Concord Biotech Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 2,407.97 million compared to INR 2,406.83 million a year ago. Revenue was INR 2,489.84 million compared to INR 2,499.33 million a year ago. Net income was INR 775.73 million compared to INR 773.68 million a year ago. Basic earnings per share from continuing operations was INR 7.41 compared to INR 7.4 a year ago. Diluted earnings per share from continuing operations was INR 7.41 compared to INR 7.4 a year ago.
For the nine months, sales was INR 6,979.7 million compared to INR 5,805.83 million a year ago. Revenue was INR 7,209.38 million compared to INR 6,036.92 million a year ago. Net income was INR 2,130.87 million compared to INR 1,485.94 million a year ago. Basic earnings per share from continuing operations was INR 20.37 compared to INR 14.2 a year ago. Diluted earnings per share from continuing operations was INR 20.37 compared to INR 14.2 a year ago.